Skip to main content
. 2023 Jun 11;15(6):1350. doi: 10.3390/v15061350

Figure 1.

Figure 1

Virologic response (FDA Snapshot algorithm) at week 144 by archived resistance class for all participants in the ITT-E population with available proviral baseline genotypic data (PRSAP) in the DTG/3TC and TAF-based regimen groups. DTG, dolutegravir; FDA, US Food and Drug Administration; INSTI, integrase strand transfer inhibitor; ITT-E, intention-to-treat exposed; NRTI, nucleoside reverse transcriptase inhibitor; PRSAP, proviral DNA resistance Snapshot Analysis population; TAF, tenofovir alafenamide; 3TC, lamivudine.